Biospecimen Processing

急性和慢性肺结核患者临床标本的控制性采集和处理 白血病、骨髓增生异常综合征（MDS）和骨髓增生性疾病（MPD）是治疗白血病的关键活性。 一个有效和全面的计划，在血液恶性肿瘤的转化研究。因此，委员会建议， 生物样本核心（核心A）有一个首要目标：我们将收集、储存、处理和分发 来自该机构诊断为白血病、MDS和MPD的所有患者的生物标本， 促进基于生物标志物的转化研究：我们将从骨骼中收集恶性细胞群 骨髓抽吸物和外周血，以及皮肤穿刺活检和口腔灌洗标本 代表非恶性细胞群。将采集血清和血浆用于将来的蛋白质组学研究。 生物标记物研究。将在每个患者的整个病程中收集标本（初始表现， 缓解、复发），并且在适当的情况下，将检索来自先前恶性肿瘤的存档标本。 特别注意标本采集（例如：快速处理白血病细胞以保存转录物 将实行质量控制。标本将被处理成细胞RNA、基因组DNA， 全基因组扩增的DNA和蛋白质提取物，如每项研究所需。细胞群也将 为将来的异种移植研究提供可行的冷冻。与流式细胞术共享资源合作， 在我们的癌症中心，我们将处理和分发来自流式细胞分选细胞群的标本。在 与我们的细胞遗传学和细胞基因组学临床实验室合作，我们将确保所有 用于研究的标本广泛而准确地注释了分子诊断数据。的 该核心的目标将通过扩大完善的癌症中心肿瘤的范围来实现 Bank和正在进行的P01资助工作，以收集AML和MDS生物标本进行基因组分析。 具体来说，戈尔A公司将扩大白血病患者的数量和类型， 收集，并作为一个渠道（通过数据和标本共享），以允许更广泛的各种 使用新的和以前储存的生物标本进行的恶性血液病转化研究。 相关性（参见说明）： 拟议的研究将导致对发病机制的更好理解和新的方法 涉及血液恶性肿瘤的检测、预防和治疗。

The controlled collection and processing of clinical specimens from patients with acute and chronic leukemias, myelodysplastic syndromes (MDS), and myeloproliferative disorders (MPD) is a critical activity for an efficient and comprehensive program in translational research in hematologic malignancies. Accordingly, the Biospecimen Core (Core A) has one overarching aim: We will collect, store, process, and distribute biospecimens from all patients with a diagnosis of leukemia, MDS, and MPD seen at this institution to facilitate biospecimen-based translational research: We will collect malignant cell populations from bone marrow aspirates and peripheral blood, as well as skin punch biopsy and buccal lavage specimens representing non-malignant cell populations. Serum and plasma will be collected for future proteomic biomarker studies. Specimens will be collected throughout each patient's disease course (initial presentation, remission, relapse) and where appropriate, archival specimens from previous malignancies will be retrieved. Particular attention to specimen procurement (eg. rapid processing of leukemia cells to preserve transcript profiles) and quality control will be practiced. Specimens will be processed to cellular RNA, genomic DNA, whole genome amplified DNA, and protein extracts as required for each study. Cellular populations will also be viably frozen for future xenograft studies. In collaboration with the Flow Cytometry Shared Resource of our Cancer Center, we will process and distribute specimens from flow-sorted cell populations. In collaboration with our clinical Laboratory of Cytogenetics and Cytogenomics, we will ensure that all specimens used for research are extensively and accurately annotated with molecular diagnostic data. The aims of this Core will be accomplished by expanding the scope of a well-established Cancer Center Tumor Bank and an on-going, funded P01 effort to collect AML and MDS biospecimens for genomic analysis. Specifically, Gore A will expand the number and types of leukemia patients from whom biospecimens will be collected, and serve as a conduit (through data and specimen sharing) to allow for a broader variety of translational research studies in hematologic malignancies, using new and previously banked biospecimens. RELEVANCE (See instructions): The proposed studies will lead to both an improved understanding of the pathogenesis and new approaches to the detection, prevention and treatment of hematologic malignancies.